DexCom/$DXCM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
$DXCM
Sector
Primary listing
Employees
10,250
Headquarters
Website
DexCom Metrics
BasicAdvanced
$26B
36.52
$1.80
1.52
-
Price and volume
Market cap
$26B
Beta
1.52
52-week high
$93.25
52-week low
$54.11
Average daily volume
7.3M
Financial strength
Current ratio
1.565
Quick ratio
1.346
Long term debt to equity
49.342
Total debt to equity
94.479
Interest coverage (TTM)
40.93%
Profitability
EBITDA (TTM)
1,022.1
Gross margin (TTM)
58.36%
Net profit margin (TTM)
15.96%
Operating margin (TTM)
17.22%
Effective tax rate (TTM)
24.85%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
6.75%
Return on equity (TTM)
30.63%
Valuation
Price to earnings (TTM)
36.521
Price to revenue (TTM)
5.684
Price to book
9.39
Price to tangible book (TTM)
9.76
Price to free cash flow (TTM)
24.174
Free cash flow yield (TTM)
4.14%
Free cash flow per share (TTM)
2.714
Growth
Revenue change (TTM)
14.21%
Earnings per share change (TTM)
7.76%
3-year revenue growth (CAGR)
17.37%
10-year revenue growth (CAGR)
28.94%
3-year earnings per share growth (CAGR)
44.54%
10-year earnings per share growth (CAGR)
25.60%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
DexCom News
AllArticlesVideos
DXCM DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM
Newsfile Corp·1 day ago
DXCM DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - DXCM
Newsfile Corp·2 days ago
DXCM DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - DXCM
Newsfile Corp·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $26B as of December 10, 2025.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 36.52 as of December 10, 2025.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of December 10, 2025.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.